Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing

Eyes R&D In Less Crowded Sectors

Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.

Poring Studio/Shutterstock.com
Ark Biosciences refocuses on hometurf, aiming for Shanghai IPO • Source: Shutterstock

More from China

More from Focus On Asia